Current View of the Budd-Chiari Syndrome Clinical Approach |Biomedgrid
Journal: American Journal of Biomedical Science & Research (Vol.11, No. 2)Publication Date: 2020-12-04
Authors : Angélica Sabino Pereira Rodrigues; Isabelle Costa Gualberto Rosalino; João Vitor Emidio Oliveira; Brian França dos Santos;
Page : 130-132
Keywords : Hepatic Obstruction of Venous Flow; Etiology; Treatment; Diagnosis; Pathogenesis;
Abstract
The Budd-Chiari Syndrome (SBC) was first mentioned in 1845 by George Budd, a British physician who associated liver thrombosis with liver abscess, and then in 1899 by Hans Chiari, an Austrian pathologist, who delimited a clinical and pathological condition relating to the disease of primary obliterative endophlebitis. The disease became known as Budd-Chiari syndrome [1-3]. The Budd-Chiari syndrome is a rare disease in which obstruction of the hepatic veins occurs, which can be thrombotic or non-thrombotic, thus leads to a progressive centrilobular liver retention, resulting in cirrhosis [1,4]. This thrombus can occur anywhere in the venous pathway, from the hepatic venules to the junction of the inferior vena cava to the right atrium [1]. The causes that determine SBC include coagulation abnormality, trauma, tumor extension (neoplasia) or obstructive congenital abnormalities (thrombophilia) [3].
Other Latest Articles
- A Stepwise Infection and Immunity Strategies to Prevent and Treat an Emerging Infection |Biomedgrid
- Why the Biomedical Research Paradigm Must Change if we are to Win the “War on Cancer” |Biomedgrid
- Scenario of Chronic Hydroarsenicism in Arid Zones and Toxic Risk in Goats |Biomedgrid
- COVID-19 hospital admission appropriateness analysis |Biomedgrid
- Analysis of Stunting Risk in Couple of Reproductive Age in Pidie District
Last modified: 2023-07-12 22:09:28